Patents by Inventor Jonas Odgaard PETERSEN

Jonas Odgaard PETERSEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEPTIDE-DRUG CONJUGATES FOR TREATMENT OF NEURODEGENERATIVE DISEASES
    Publication number: 20250025566
    Abstract: The present invention relates to a conjugated molecule for use in treatment and/or prevention of a neurodegenerative disease in a subject in need thereof, the conjugated molecule comprising a peptide and a N-methyl-D-aspartate receptor (NMDAR) antagonist, wherein the peptide is a glucagon superfamily peptide, the peptide being linked to the NMDAR antagonist either directly or through a chemical linker.
    Type: Application
    Filed: December 2, 2022
    Publication date: January 23, 2025
    Inventors: Christoffer CLEMMENSEN, Jonas Odgaard PETERSEN, Anders Bue KLEIN
  • CONJUGATES OF GLUCAGON AND AMPK ACTIVATORS
    Publication number: 20240408218
    Abstract: The present invention relates to a conjugated molecule comprising a peptide displaying at least 0.1% activity of native glucagon at the glucagon receptor, and a AMP-activated protein kinase (AMPK) activator, the peptide being covalently bonded to the AMPK activator either directly or through a linker, the conjugated molecule for use in therapy, a pharmaceutical composition comprising the conjugated molecule, a method of reducing body weight of a mammal comprising administering the conjugated molecule to the mammal, and a non-therapeutic method of reducing body weight of a mammal comprising orally administering the conjugated molecule to the mammal.
    Type: Application
    Filed: September 28, 2022
    Publication date: December 12, 2024
    Inventors: Christoffer CLEMMENSEN, Anders Bue KLEIN, Jonas Odgaard PETERSEN, Kei SAKAMOTO
  • GLP1R AGONIST NMDAR ANTAGONIST CONJUGATES
    Publication number: 20230183335
    Abstract: The present invention relates to a conjugated molecule comprising a peptide displaying at least 0.1% activity of native glucagon-like peptide 1 (GLP-1) at the GLP-1 receptor, and an N-methyl-D-aspartate receptor (NMDAR) antagonist, the peptide being covalently bonded to the NMDAR antagonist either directly or through a chemical linker, the conjugated molecule for use in therapy, pharmaceutical composition comprising the conjugated molecule, a method of reducing body weight of a mammal comprising administering the conjugated molecule to the mammal, and a non-therapeutic method of reducing body weight of a mammal comprising orally administering the conjugated molecule to the mammal.
    Type: Application
    Filed: June 3, 2021
    Publication date: June 15, 2023
    Inventors: Christoffer CLEMMENSEN, Anders Bue KLEIN, Jonas Odgaard PETERSEN, Bente Flensborg FRØLUND, Kristian STRØMGAARD